Receptor Activation of HIV-1 Env Leads to Asymmetric Exposure of the gp41 Trimer

被引:30
作者
Khasnis, Mukta D. [1 ]
Halkidis, Konstantine [1 ,2 ]
Bhardwaj, Anshul [1 ]
Root, Michael J. [1 ]
机构
[1] Thomas Jefferson Univ, Dept Biochem & Mol Biol, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA
[2] Drexel Univ, Coll Med, Dept Med, Hahnemann Univ Hosp, Philadelphia, PA 19104 USA
基金
美国国家卫生研究院;
关键词
IMMUNODEFICIENCY-VIRUS TYPE-1; COOPERATIVE SUBUNIT INTERACTIONS; HUMAN MONOCLONAL-ANTIBODY; CRYO-EM STRUCTURE; ENVELOPE GLYCOPROTEIN; MEMBRANE-FUSION; COILED-COIL; SOLUBLE CD4; PEPTIDE INHIBITORS; SYNTHETIC PEPTIDE;
D O I
10.1371/journal.ppat.1006098
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Structural rearrangements of HIV-1 glycoprotein Env promote viral entry through membrane fusion. Env is a symmetric homotrimer with each protomer composed of surface subunit gp120 and transmembrane subunit gp41. Cellular CD4- and chemokine receptor-binding to gp120 coordinate conformational changes in gp41, first to an extended prehairpin intermediate (PHI) and, ultimately, into a fusogenic trimer-of-hairpins (TOH). HIV-1 fusion inhibitors target gp41 in the PHI and block TOH formation. To characterize structural transformations into and through the PHI, we employed asymmetric Env trimers containing both high and low affinity binding sites for individual fusion inhibitors. Asymmetry was achieved using engineered Env heterotrimers composed of protomers deficient in either CD4- or chemokine receptor-binding. Linking receptor engagement to inhibitor affinity allowed us to assess conformational changes of individual Env protomers in the context of a functioning trimer. We found that the transition into the PHI could occur symmetrically or asymmetrically depending on the stoichiometry of CD4 binding. Sequential engagement of multiple CD4s promoted progressive exposure of individual fusion inhibitor binding sites in a CD4-dependent fashion. By contrast, engagement of only a single CD4 molecule led to a delayed, but symmetric, exposure of the gp41 trimer. This complex coupling between Env-CD4 interaction and gp41 exposure explained the multiphasic fusion-inhibitor titration observed for a mutant Env homotrimer with a naturally asymmetric gp41. Our results suggest that the spatial and temporal exposure of gp41 can proceed in a nonconcerted, asymmetric manner depending on the number of CD4s that engage the Env trimer. The findings have important implications for the mechanism of viral membrane fusion and the development of vaccine candidates designed to elicit neutralizing antibodies targeting gp41 in the PHI.
引用
收藏
页数:29
相关论文
共 50 条
  • [1] Designing a Soluble Near Full-length HIV-1 gp41 Trimer
    Gao, Guofen
    Wieczorek, Lindsay
    Peachman, Kristina K.
    Polonis, Victoria R.
    Alving, Carl R.
    Rao, Mangala
    Rao, Venigalla B.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2013, 288 (01) : 234 - 246
  • [2] Asymmetric Deactivation of HIV-1 gp41 following Fusion Inhibitor Binding
    Kahle, Kristen M.
    Steger, H. Kirby
    Root, Michael J.
    PLOS PATHOGENS, 2009, 5 (11)
  • [3] Regulation of epitope exposure in the gp41 membrane-proximal external region through interactions at the apex of HIV-1 Env
    Schapiro, Hannah M.
    Khasnis, Mukta D.
    Ahn, Koree
    Karagiaridi, Alexandra
    Hayden, Stephanie
    Cilento, Maria E.
    Root, Michael J.
    PLOS PATHOGENS, 2022, 18 (05)
  • [4] Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike
    Lee, Jeong Hyun
    Leaman, Daniel P.
    Kim, Arthur S.
    de la Pena, Alba Torrents
    Sliepen, Kwinten
    Yasmeen, Anila
    Derking, Ronald
    Ramos, Alejandra
    de Taeye, Steven W.
    Ozorowski, Gabriel
    Klein, Florian
    Burton, Dennis R.
    Nussenzweig, Michel C.
    Poignard, Pascal
    Moore, John P.
    Klasse, Per Johan
    Sanders, Rogier W.
    Zwick, Michael B.
    Wilson, Ian A.
    Ward, Andrew B.
    NATURE COMMUNICATIONS, 2015, 6
  • [5] θ-defensins prevent HIV-1 Env-mediated fusion by binding gp41 and blocking 6-helix bundle formation
    Gallo, Stephen A.
    Wang, Wei
    Rawat, Satinder S.
    Jung, Grace
    Waring, Alan J.
    Cole, Alexander M.
    Lu, Hong
    Yan, Xuxia
    Daly, Norelle L.
    Craik, David J.
    Jiang, Shibo
    Lehrer, Robert I.
    Blumenthal, Robert
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (27) : 18787 - 18792
  • [6] Neutralizing Antibodies Targeting HIV-1 gp41
    Caillat, Christophe
    Guilligay, Delphine
    Sulbaran, Guidenn
    Weissenhorn, Winfried
    VIRUSES-BASEL, 2020, 12 (11):
  • [7] Identification and characterization of a subpocket on the N-trimer of HIV-1 Gp41: implication for viral entry and drug target
    Qiu, Zonglin
    Chong, Huihui
    Yao, Xue
    Su, Yang
    Cui, Sheng
    He, Yuxian
    AIDS, 2015, 29 (09) : 1015 - 1024
  • [8] HIV-1 gp41 transmembrane oligomerization monitored by FRET and FCS
    Schroeder, Sabrina
    Kaufman, Joshua D.
    Grunwald, Matthias
    Walla, Peter J.
    Lakomek, Nils-Alexander
    Wingfield, Paul T.
    FEBS LETTERS, 2018, 592 (06): : 939 - 948
  • [9] Evaluation of a synthetic C34 trimer of HIV-1 gp41 as AIDS vaccines
    Hashimoto, Chie
    Nomura, Wataru
    Ohya, Aki
    Urano, Emiko
    Miyauchi, Kosuke
    Narumi, Tetsuo
    Aikawa, Haruo
    Komano, Jun A.
    Yamamoto, Naoki
    Tamamura, Hirokazu
    BIOORGANIC & MEDICINAL CHEMISTRY, 2012, 20 (10) : 3287 - 3291
  • [10] Development of HIV-1 Fusion Inhibitors Targeting gp41
    Lu, K.
    Asyifah, M. R.
    Shao, F.
    Zhang, D.
    CURRENT MEDICINAL CHEMISTRY, 2014, 21 (17) : 1976 - 1996